Background: Studies in animal models of inflammatory bowel disease (IBD) suggest that supplementation of total parenteral nutrition with glutamine (gln), a conditionally essential amino acid in catabolic conditions, increases gln plasma concentrations, reduces intestinal damage, improves nitrogen balance and may improve the course of the disease. However, human data supporting this assumption are missing. Methods: A total of 24 consecutive patients with an acute exacerbation of IBD (19 Crohn's disease; five ulcerative colitis) and scheduled for total parenteral nutrition (TPN) (47 days) were randomised. Parallel to a standardised anti-inflammatory therapy, the patients received either a TPN with 1.5 g/kg body weight of a standard amino acid or an isonitrogenic, isocaloric TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine. Primary end points were gln plasma concentrations and intestinal permeability assessed by urinary lactulose and D-xylose ratio. Results: Gln plasma levels did not differ significantly in either group throughout the study. Intestinal permeability did not change within 7 days either with or without gln supplementation (D-lactulose/xylose ratio: 0.0170.05 (gln þ ) vs 0.0270.1 (glnÀ)). The observed changes in inflammatory and nutritional parameters, and also disease activity, length of TPN and hospital stay, were independent of glutamine substitution. Five (41%) patients in the gln þ group and three (25%) patients in the glnÀ group needed surgical intervention. Conclusion: Although limited by the sample size, these results do not support the hypothesis that glutamine substitution has an obvious biochemical or clinical benefit in patients with active IBD scheduled for total parenteral nutrition.
Introduction
The standard therapy for patients with an acute exacerbation of an inflammatory bowel disease (IBD) is immunosuppression, achieved mainly with steroids. IBD includes patients with Crohn's disease and ulcerative colitis. Both diseases are characterised by damage of the epithelium and especially in Crohn's diseases by an impaired intestinal barrier function. There is growing evidence that an increased mucosal invasion of bacteria (Swidsinski et al, 2002) or an enhanced presentation of bacterial antigens to immunocompetent cells are critical steps in the pathogenesis of IBD (Stallmach et al, 1998) . In addition, endotoxinaemia derived from the gut (Gardiner and Rowlands, 1995) might increase the ability of inflammatory cells such as monocytes to produce proinflammatory cytokines like interleukin 6 (IL-6) and tumour necrosis factor-a (TNF-a). Both cytokines are found elevated in active IBD, and treatment with anti-TNF-a antibodies was found to be effective in active Crohn's disease (Stallmach et al, 1998) .
Total parenteral nutrition is thought to be useful for patients who cannot be nourished adequately by enteral nutrition (Podolsky, 2002) . When TPN is given, further impairment of the intestinal epithelial barrier must be considered (van der Hulst et al, 1993 , Oriishi et al, 1995 . IBD patients with acute exacerbation, bowel rest and TPN may, therefore, have a particular need for enterocyte support, for example, by glutamine (gln) administration (Scheppach et al, 1994) . The intestinal barrier is composed of several elements, that is, the mucous layer, the epithelium and the gut-associated lymphoid tissue (GALT) . It has been clearly demonstrated that glutamine supplementation improves nitrogen balance, enhances the rate of protein synthesis, supports growth of enterocytes and immune cells, and is thus essential for maintaining the integrity of the mucosa (Smith, 1997; Elia, 1999) . In addition, gln preserves the glutathione (GSH) stores that we know function as a major cellular antioxidative protection system (Harward et al, 1994) . In this way, gln becomes an 'essential' amino acid during catabolic states which occur in stress phases (Furst et al, 1997) . For a long time, gln could not be used for parenteral administration because of its limited solubility and stability in water, but this changed once glutamine dipeptides became available (Furst et al, 1997) .
From a theoretical point of view, it is especially important to supplement TPN with gln in IBD patients. However, clinical data supporting this assumption are rare. Only two studies have been published in which gln was administered by an enteral route in 18 and 14 IBD patients (Den Hond et al, 1999; Akobeng et al, 2000) . This means that data are only available for 16 IBD patients treated with gln. Akobeng et al (2000) investigated a glutamine-enriched enteral diet in children, and Den Hond et al (1999) tested a gln supplement vs placebo in adults with Crohn's disease. A significant beneficial effect of gln supplementation, compared to placebo or a standard enteral formula, was not demonstrated. No data are available on IBD patients requiring parenteral nutrition. We therefore compared IBD patients on TPN supplemented with 0.3 g/kg/day alanyl-glutamine with patients on a standard isonitrogenic TPN without glutamine.
Patients and methods

Subjects
Over a period of 49 months, 39 consecutive adult patients with active IBD intended for TPN at the Department of Gastroenterology were screened. In our department, every TPN was prescribed and supervised by a specialised multidisciplinary nutrition support team. However, primary decision for TPN was taken by the responsible ward physicians and was based on intolerance to enteral nutrition due to disease activity or stenosis of the bowel. In addition, TPN was indicated when adequate caloric intake could not be maintained by oral intake (including sip feeding) or enteral tube feeding over a period of at least 5 days.
Patients not consenting to the study, patients who were on TPN within 2 weeks before the study, pregnant patients, patients with renal failure (creatinine 4150 mmol/l) and patients thought to be capable of eating within 1 week were excluded. Randomization was achieved by the drawing of a numbered sealed envelope, with the designated treatment groups generated by random order sequence. The study investigators were not aware in advance to which group the patients would be assigned. Also the patients, the nurses and the primary physicians responsible for all clinical decisions (including discontinuing TPN and hospital discharge) were unaware of who belonged to which group. The exact contents of the all in one TPN solution was blinded.
The local ethical committee approved the study and patients gave written informed consent.
Methods TPN was administered for at least 1 week in all cases. Quantity and composition were calculated on an individual basis with the following regimen. The resting energy expenditure (REE) of each patient was estimated using the Harris and Benedict formula. To estimate total energy expenditure (EE), REE was multiplied by 1.5. This factor was lowered to 1.2 when patients were immobilised or had signs of systemic inflammation (elevated body temperature 438.51C, WBC 412 000/ml, CRP 450 mg/l). The EE thus determined was allocated to energy supply in the form of amino acids (1.5 g/kg/day), glucose and lipids, with 60% of non-amino-acid energy given as glucose and 40% of nonamino-acid energy as lipids. Patients in the control group (glnÀ) received 1.5 g/kg/day amino acids in a standard aminoacid solution (Aminoplasmal s 10%, B Braun, Melsungen, Germany). This solution does not contain any glutamine. Patients in the glutamine group (gln þ ) received 0.3 g/kg/day alanyl-glutamine (Dipeptamin s , Fresenius, Germany; resulting in 0.2 g/kg/day glutamine), which was added to 1.2 g/kg/day of standard amino-acid solution.
All feeds contained a full complement of trace elements (5 ml Inzolen s infantibus, Dr Köhler Chemie, Alsbach, Germany) and vitamins (1 amp of Soluvit s and 10 ml Vitalipid adult, Pharmacia, Erlangen, Germany). Sodium, phosphate, potassium, magnesium and calcium requirements were individualised, closely so for the latter electrolytes, and volume was determined according to the patient's needs and losses. During parenteral feeding, patients were allowed to drink a maximum of 500 ml of water or tea if clinically permitted.
Protocol
The main study end points were (i) gln plasma concentrations and (ii) intestinal permeability with and without glutamine substitution during TPN. Secondary end points were protein catabolism, disease activity, infectious complications and duration of TPN.
Study-related clinical and laboratory evaluation was carried out at the start of TPN (day 0), day 7 and day 14. In patients with Crohn's disease, the Crohn's disease activity index (CDAI), a measure for the clinical condition of the patient, was calculated as described (Podolsky, 2002) . A blood sample was taken to measure haemoglobin, haematocrit, lymphocyte and leukocyte counts. Serum concentration of albumin, C-reactive protein (CRP), urea and plasma amino acid (AA) concentrations were determined. Albumin and urea were measured by standard in-house methods. The CRP level was quantitatively measured by particle-enhanced nephelometry with a typical detection limit of 5 mg/l (Behringwerke, Marburg, Germany). For AA analysis, plasma and urine was deproteinised with 5% sulphosalicylic acid. Aliquots were stored at À801C and later analysed by automated ion-exchange chromatography on an automated amino-acid analyser (Liquimat 5001, Fa Biotronic, Munich, Germany) (Ockenga et al, 2000) .
Apart from TPN, all patients underwent the same drug therapy concept. (Podolsky, 2002) . Weekly reductions to immunosuppressive therapy reflected the patient's clinical condition.
Measurement of intestinal permeability
Intestinal permeability was measured before TPN and after 7 days. It was assessed on the basis of urinary lactulose and D-xylose ratio after oral challenge as described (Parrilli et al, 1989; Bjarnason et al, 1995) . After overnight fasting, baseline urine was collected and patients ingested 200 ml of the test solution containing 25 g D-xylose and 5 g lactulose. The patients continued fasting for 2 h, and urine was collected for 5 h. Lactulose and D-xylose were determined by highperformance liquid chromatography, and urinary excretion was expressed as the ratio of lactulose/xylose.
In healthy subjects, the recovery of lactulose and D-xylose in 5 h urine collection is below 1 and 30-40%, respectively (Parrilli et al, 1989) . Normal lactulose/xylose ratio values are reported to display a mean of 0.02570.0086 (range: 0.0090-0.0423) (Parrilli et al, 1989) . It has been shown that damage to the gut mucosa is followed by a rise in lactulose and a decrease in D-xylose absorption.
Statistical analysis
Statistical analysis was performed with SPSS 7.5. 2 (SPSS Inc., USA). Data are presented as mean7standard deviation (s.d.) unless indicated otherwise. Inter-and intragroup differences were subjected to analysis using Student's t-test, with the Mann-Whitney U-test for nonparametric data or Wilcoxon Rank Sum Test as indicated. The study size of 24 patients results in a power of 76% based on a one-tailed test on proportions for an increase of a 20% of the glutamine plasma concentration (increase of the plasma glutamine concentration from 5507110 mmol/l to 670 mmol/l) with the probability of a type-I error set at 5%. Probability of duration of parenteral feeding and hospitalisation were calculated with the Kaplan-Meier estimation and differences between groups were subjected to the Mantel-Haenszel test. In patients scheduled for surgery, the date of operation was used to calculate follow-up. P-values (two tailed) of less than 0.05 were considered significant.
Results
Characterisation of groups
From 39 patients screened, 19 patients with Crohn's disease and five with ulcerative colitis could be included in the study. The reasons for excluding patients from the study were patient failure to consent or proposed parenteral feeding for less then 7 days.
Patient characteristics are shown in Table 1 . The two groups yielded a similar proportion of Crohn's disease and ulcerative colitis. No distinction was made for localisation of the disease. In line with the protocol, patients in both groups received a comparable TPN composition, but aminoacid composition differed (see Table 2 ).
At baseline, there was no difference between the groups for the parameters we investigated, for example, age, nutritional status, inflammatory activity or plasma AA concentration (Tables 3 and 4) . Renal function was not significantly different between groups (serum creatinine: gln þ : 53.7716.2 mmol/l vs glnÀ: 65.5715.6 mmol/l).
Plasma AA concentrations and nutritional status Glutamine plasma levels did not change significantly in either group throughout the study (Table 4) . Although the significant increase in plasma phenylalanine and serum urea concentration in the glnÀ group indicated a pronounced catabolic status (Tables 3 and 4) , no difference in urine 3-methyl-histidine excretion could be observed in an inter-and intragroup comparison (Table 3 ). In addition, an increase of the plasma glutamate level was observed in the glnÀ group. BMI and serum albumin level did not change significantly in either group. Levels of citrulline or arginine did not change in the course of the study with or without glutamine.
Intestinal permeability
In 18 patients (14 Crohn's disease, four colitis ulcerosa), measurements of intestinal permeability were available. The mean lactulose/xylose ratio at day 0 was 0.04270.03 with no difference between Crohn's disease and Colitis ulcerosa (0.04370.038 vs 0.04070.027, n.s.). Reanalysing the total group after a 7-day period of TPN, no significant increase in intestinal permeability (lactulose/ xylose ratio on day 7: 0.05670.07, n.s.) was detectable. Glutamine supplementation did not appear to produce any significant difference in D-lactulose/xylose ratio (gln þ : 0.0170.05 vs glnÀ: 0.0270.1; P ¼ 0.82, Figure 1 ). Subgroup analysis with Crohn's and colitis patients did not alter this result (data not shown).
In patients with Crohn's disease, severity of disease (expressed as CDAI) was independent of intestinal permeability (r ¼ 0.28, n.s.). There was no significant difference between patients in terms of an increased, decreased or unchanged intestinal permeability after 7 days. In all Crohn's patients, the decrease in CDAI was analogous. Course of disease and medication Glutamine supplementation exerted no specific effect on disease activity (CDAI), WBC or total lymphocyte count compared to standard TPN (Table 3) . Individual changes in CDAI are shown in Figure 2 . There was no difference in frequency of diarrhoea, pain or extra-intestinal manifestation (data not shown). Specific clinical symptoms related to UC were not evaluated due to the small sample size. In addition, glutamine supplementation had no effect on reductions in standard anti-inflammatory therapy during the study period. All patients were treated with mesalazine (gln þ : 36007630 mg; glnÀ: 367071031 mg) and prednisolone. There was no difference in prednisolone dose between the two groups at day 0 (gln þ : 0.8570.66 mg/kg/day; gln þ vs glnÀ: 0.7370.20 mg/kg/day; glnÀ) or at day 14 (gln þ : 0.7670.39 mg/kg/day vs glnÀ: 0.5770.3 mg/kg/day). One patient in the glutamine group was additionally treated with azathioprine (Imurek s , Glaxo Wellcome, Hamburg) compared to three patients in the control group.
Five (41%) patients in the gln þ group and three (25%) patients in the glnÀ group were scheduled for surgical resection due to failure of conservative therapy or obstruction. No patients with UC needed colonic resection.
Infectious complications, duration of TPN and hospital stay Duration of TPN and length of hospital stay (LOS) did not differ significantly between patients with or without glutamine (TPN gln þ 24 (17-36) days vs glnÀ 19 (14-21) days; LOS 34 (27-54) days vs 38 (24-48)).
Three catheter infections with positive blood cultures were diagnosed in the glutamine group, but none in the control group.
Discussion
Our data indicate that (i) a 7-day period of TPN and bowel rest yields no additional negative effect on intestinal permeability in patients with an acute exacerbation of IBD and (ii) that a glutamine supplementation for 7 days with 0. 2 g/kg/day (0.3 g/kg/day alanyl-glutamine) does not improve intestinal permeability, inflammation or nutritional parameters.
In patients with IBD unable to eat or feed by the enteral route for a prolonged period, parenteral nutritional support is included in management (Gassull & Cabre, 2001) .
Early literature indicated that TPN may lead to an atrophy of the intestinal mucosa with reduced villous height and a reduction in enterocyte mass (Koga et al, 1975; Buchman et al, 1995) . Increased intestinal permeability is a frequent finding in patients with intestinal inflammatory disorders (Katz et al, 1989; Resnick et al, 1990) . For Crohn's in particular, it has been proposed as a pathophysiological event in the development of the disease (Podolsky, 2002; Swidsinski et al, 2002) . van der Hulst et al (1993) observed in a small subgroup of IBD patients that additional gln supplementation may prevent the negative effects of TPN on gut mucosa. This tempted us to study gln supplementation in IBD patients receiving TPN. Figure 2 Crohn's disease activity index (CDAI) before and after treatment in patients on glutamine supplemented parenteral nutrition (gln þ ) and patients on standard parenteral nutrition without glutamine (glnÀ). The patients with colitis ulcerosa were excluded.
However, our study was unable to confirm the hypothesis of glutamine's beneficial effect. With a sample size of 24 patients, our study has a power of 80% to detect a difference between the two groups of at least B20% increase in gln plasma concentrations, B40% in the lactulose/xylose ratio, or B30% in CRP serum concentrations. We cannot rule out the possibility that we failed to detect smaller differences in our patients. To ultimately test a clinical benefit with primary end points like remission rates, infectious complications or avoidance of surgery sample sizes of approximately 200 patients are necessary. However, a recent review challenges the theory that TPN alone accounts for the relevant increase in intestinal permeability (Jeejeebhoy, 2001 ). Jeejeebhoy reports that significant intestinal atrophy did not occur within 1 month of complete bowel rest and was only observed when TPN was given over a longer period. This would indicate that we missed this effect, because we looked only for short-term changes.
Studies in animal models of inflammatory bowel diseases have indicated potentially beneficial effects of glutamine supplementation (Fujita & Sakurai, 1995; Ameho et al, 1997) , but this may not be related simply to an improvement in the intestinal function and barrier. In animals and man, enteral or parenteral nutrition supplemented with glutamine is associated with improved lymphocyte function and antioxidant capacity compared to standard TPN (Furst et al, 1997) . In various catabolic situations, glutamine administration resulted in a significant decrease in morbidity and mortality (Jiang et al, 1993; Furst et al, 1997; Houdijk et al, 1998) . We have observed a beneficial effect on disease activity, lymphocyte count and inflammatory parameters such as CRP in patients with acute pancreatitis (Ockenga et al, 2002) . One explanation for the absent effect in IBD patients could be the overwhelming therapeutic effect of standard antiinflammatory therapy with steroids or azathioprine.
Glutamine is the most abundant free amino acid in the body with a central role to play in many metabolic processes (eg as a vehicle for interorgan transport of nitrogen and carbon skeletons, a precursor for nucleotides and glutathione, and a regulator of acid-base balance) (Furst et al, 1997) . In the total population, plasma AA analysis revealed no differences in plasma glutamine concentrations between the two study groups during the course of the study. A recent publication on 15 N-labelled-glutamine kinetics in patients scheduled for gastrointestinal surgery showed an almost identical increase of plasma glutamine levels in patients with or without a glutamine-dipeptide-supplemented TPN (van Acker et al, 2000) . However, the total glutamine profile and tissue glutamine utilisation only increased in the glutaminesupplemented patients. Patients with inflammatory bowel disease are in a state of catabolism (Thomas et al, 1992) and have an increased risk for development of malnutrition, especially during an acute exacerbation of the disease (Geerling et al, 1998) . Indeed, a significant increase of serum urea and plasma phenylalanine concentrations in the control group alone suggests improved nitrogen balance in the glutamine group. This effect of a glutamine supplementation has been shown in surgical patients, too (Hammarqvist et al, 1989; Stehle et al, 1989) . However, these data were not supported by the findings on urine 3-methyl-histidine excretion rate, which is a reliable marker for catabolic muscle degradation (McNurlan et al, 1997) . In addition, we did not observe an effect of glutamine supplementation on citrulline and arginine plasma concentrations. Citrulline and arginine are breakdown products of glutamine metabolism in enterocytes (McAnena et al, 1991) and have been identified as an indirect parameter of enterocyte function in the small bowel (Crenn et al, 2000) . The increase of glutamate in the glnÀ group may indicate a disturbed glutathione synthesis and therefore an impaired antioxidative capacity, but this has to be proven by further adequate investigations (Wu et al, 2004) .
These are the first human data on parenteral glutamine support in IBD patients. Two published human studies on enteral glutamine supplementation in patients with Crohn's disease included a total number of 32 patients (14 adults, 18 children) (Den Hond et al, 1999; Akobeng et al, 2000) . Neither study observed an effect of enteral glutamine supplementation (over a 4-week period) on intestinal permeability or inflammatory activity. Rather, in the study by Akobeng et al, glutamine seemed to be less effective in improving paediatric CDAI.
The majority of our patients suffered from Crohn's disease, but we also included patients with colitis ulcerosa. We did not perform a subgroup analysis according to the severity and localisation of the inflammatory bowel disease, because this would have resulted in numbers too small for statistical analysis. Crohn's disease and colitis ulcerosa can reflect different pathophysiological backgrounds, and the individual indication for TPN may vary. We decided to study both groups because we primarily wanted to investigate whether patients with bowel disease who did not tolerate enteral nutrition and were scheduled for TPN might benefit from glutamine supplementation with respect to AA pattern and intestinal permeability. Moreover, excluding the colitis, ulcerosa patients did not alter the data.
There are other explanations for why glutamine supplementation might not prove beneficial in IBD. The ability of glutamine to enhance T-cell function could promote inflammatory activity in Crohn's disease (O'Riordain et al, 1994) . A further negative effect of increased glutamine supplementation may relate to the fact that glutamine is a precursor of nitric oxide. Excessive nitric oxide has been shown to contribute to inflammation in both Crohn's disease and ulcerative colitis (Rachmilewitz et al, 1995) . Indeed, in rats, excess glutamine exacerbates trinitrobenzenesulphonic acidinduced colitis (Shinozaki et al, 1997) . Apart from lymphocyte count, we did not perform lymphocyte function tests, neither did we measure nitric oxide generation. We cannot, therefore, state definitely whether glutamine modulated these parameters in our patients.
Conclusion
Although limited by the small sample size, our results do not support the hypothesis that glutamine-enriched parenteral nutrition for IBD patients can maintain or improve the gut mucosal barrier, inflammatory activity or nutritional status. Many clinical studies have documented a beneficial effect of enteral or parenteral glutamine in various catabolic conditions, and this may not be simply extrapolated to IBD.
